A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer

Sponsor
Hoffmann-La Roche
Study ID
NCT01066884
Phase
PHASE4
Status
Completed

Conditions

  • Non-Squamous Non-Small Cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This single arm study will assess the safety and efficacy of Tarceva monotherapy in patients with advanced non-small cell lung cancer. Patients will receive Tarceva 150mg p.o. daily. The anticipated time on study treatment is until disease progression, and the target sample size is 100-500 individuals.

Key Dates

First listed
Feb 10, 2010
Start date
Apr 30, 2009
Status verified
Aug 2016
Primary completion
Nov 30, 2009
Completion
Nov 30, 2009

Study Design

Enrollment
5 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1

Primary Outcome Measure

Incidence of adverse events (AEs) [ Time Frame: Length of patient on study (length of time of patient on study determined by investigator) ]

Related Studies